echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Diagnostic Test > PNAS analysis: Develop a new type of cancer immunity that can target common genetic mutations...

    PNAS analysis: Develop a new type of cancer immunity that can target common genetic mutations...

    • Last Update: 2021-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, in a research report titled "Targeting loss of heterozygosity for cancer-specific immunotherapy" published in the international journal PNAS, scientists from Johns Hopkins University School of Medicine and other institutions have developed a new type of The prototype of cancer immunotherapy, which may be able to engineer T cells to target all common genetic alterations in cancer; this new method can stimulate the body's immune response to resist cells that lack a copy of a gene , That is, cells with loss of heterozygosity (LOH).


    A gene has two alleles or copies, and the two copies are from the parent's body; cancer-related genetic changes usually involve the loss of one of the gene copies.


    CARs are engineered receptors that can bind to special antigens on the surface of cancer cells.


    The researcher Michael Hwang explained that in normal cells, both alleles are present and expressed.


    The researchers tested the NASCAR therapy in three separate cell lines and mouse models, including mouse models with or without LOH, to confirm the specificity of this method for genetic changes.


    Researcher Shibin Zhou said that the research in this article provides a principled proof that this method can be used to selectively kill cancer cells; researchers may need to conduct years of research before clinical implementation.


    In recent years, scientists have clearly realized that the immune system is a powerful tool to fight cancer.


    [1] Michael S.


    [1] Michael S.


    【2】Cancer immunotherapy approach targets common genetic alteration

    by Johns Hopkins University School of Medicine

    by Johns Hopkins University School of Medicine

    This article is from Biological Valley, for more information, please download Biological Valley APP (

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.